XT
PVLA

XTX Topco’s Palvella Therapeutics PVLA Stock Holding History

XTX Topco’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
8,861
+3,033
+52% +$368K 0.02% 1501
2026
Q1 		$726K Buy
5,828
+1,725
+42% +$180K 0.01% 1702
2025
Q4 		$429K Buy
+4,103
New +$350K 0.01% 1745
2025
Q3 		– Sell
-17,701
Closed -$399K – 3473
2025
Q2 		$399K Buy
+17,701
New +$415K 0.02% 1255
2024
Q2 		– Sell
-259
Closed -$3.8K – 2569
2024
Q1 		$3.8K Sell
259
-237
-48% -$3.3K ﹤0.01% 1737
2023
Q4 		$7.22K Buy
+496
New +$9.08K ﹤0.01% 1457
2022
Q3 		– Sell
-1,244
Closed -$186K – 1436
2022
Q2 		$186K Buy
1,244
+1,056
+562% +$193K 0.08% 484
2022
Q1 		$46K Buy
+188
New +$49.4K 0.02% 599
2021
Q4 		– Sell
-408
Closed -$169K – 1051
2021
Q3 		$169K Buy
408
+182
+81% +$63.4K 0.06% 529
2021
Q2 		$69K Buy
226
+84
+59% +$18.4K 0.02% 698
2021
Q1 		$29K Buy
+142
New +$31K 0.01% 649

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

XTX Topco's PVLA Position: Q2 2026 in Review

XTX Topco increased its Palvella Therapeutics (PVLA) stake by 52% in Q2 2026, buying an estimated $368K and bringing the position to 8,861 shares worth $1.35M. The position accounts for 0.02% of the portfolio, ranked #1501.

XTX Topco first reported a position in PVLA in Q1 2021 and has held it in 11 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • XTX Topco held 8,861 shares of Palvella Therapeutics worth $1.35M as of Q2 2026.
  • XTX Topco bought 3,033 Palvella Therapeutics shares in Q2 2026, an estimated $368K.
  • Palvella Therapeutics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1501 holding.
  • XTX Topco first reported a position in Palvella Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.